How to Navigate Menopause & Perimenopause for Maximum Health & Vitality | Dr. Mary Claire Haver

This batch is the opening stretch of a long interview, and it starts with housekeeping rather than substance: a note that the transcript is not final, an introduction, and three sponsor segments before the first question. Huberman's framing is that Haver sits "at the center" of "a new direction for the understanding and treatment of menopause", and he previews the territory he wants to cover, including perimenopause, cardiovascular disease and osteoporosis. He also promises a discussion of hormone replacement therapy for both estrogen and testosterone, and of "the many misconceptions and controversies" around it. That promise matters, because the excerpt that follows delivers the diagnostic and lifestyle half of the conversation and only begins to touch the therapeutic half.

The first question is definitional, and Haver's answer is a refusal. The standard definition, she says, is "one year after the final menstrual period", and she announces up front that she has "a huge problem with" it. Her objection is not academic: "not everyone has a menstrual period." A woman who has had a hysterectomy, who uses an IUD, who has had an ablation, or who has PCOS may never present the marker the definition depends on, and she extends the point to clinicians, who she says struggle to make the diagnosis because the criterion does not fit every patient.

The medical definition of menopause, which I have a huge problem with, is one year after the final menstrual period.

Her alternative is to treat the date as a formality and the process as the real subject. "Menopause is also one day of your life", she says, and what that day marks is "the end of your ovarian function", which she also calls ovarian failure or ovarian senescence. Huberman asks directly whether the field needs a redefinition, and she agrees: "defining it as the presence or absence of a period is a mistake." The disagreement here is with the diagnostic convention itself, not with any patient's experience, and it recurs later when she argues that menopause should not be defined by hot flashes either.

Haver grounds the definition in egg counts. Women are born with "one to 2 million" eggs; by 30 most have "about 10%, maybe 120,000"; by 40 they are down to "3%" of the supply, and quality declines alongside quantity. On her account the hormonal consequences follow from that depletion: estradiol falls to less than 1% of reproductive-year levels, progesterone declines, and testosterone falls to "somewhere 50% or less" of its healthiest level, though she notes that women have other routes to testosterone production.

The epidemiological anchors she gives are narrow in the middle and wide at the edges. The average age of that one-year anniversary is "about 51 to 52", but "normal is still 45 to 55," and the distribution "curves pretty wide." Perimenopause begins "seven to 10 years before that last menstrual period." Huberman's reaction is telling: he says it is the first time he has heard a specific number attached to the word, and later, when he summarizes the window as "about seven years", she corrects him to "Seven to 10".

The mechanism she walks through is a closed loop with a sensor and an amplifier. The hypothalamus monitors estradiol in the blood; when levels fall it sends GnRH to the pituitary; the pituitary emits pulses of LH and FSH; those pulses drive ovulation; and ovulation is what raises estrogen. Estrogen is therefore not simply an input to the loop but a product of it, which is why disrupting ovulation disrupts the signal the brain is listening for.

In early perimenopause, when the egg supply crosses a critical threshold, the ovary becomes less responsive to the LH and FSH surges. The brain escalates, the pituitary reports that it already sent the signal, and FSH pulses grow larger; ovulation may arrive late or not at all. Cycle timing goes "awry", periods cluster closer together or spread further apart, and estradiol swings to peaks higher than anything seen during reproductive years while the baseline underneath falls. She calls this "the zone of chaos", and the phrase is doing real work: the curve is volatile rather than merely declining.

We call it in our world the zone of chaos.

The clinical consequence is that there is no reliable blood test for perimenopause, because a single measurement of a hormone that is oscillating unpredictably carries little diagnostic information. In her practice the diagnosis is made from symptoms, with other conditions excluded. When Huberman presses on what is happening at the level of the ovary and its receptors, she is candid that the mechanism is not well characterized: egg quality is poor, the theca cells that convert testosterone to estradiol still respond but the cells are "just old," and she calls for far more research. She also notes that her own medical education, 25 years earlier, covered "the transition to menopause" as an endpoint and not the underlying endocrinology, which she says she did not learn "until about two years ago."

Huberman adds a structural explanation for the gap. Mouse studies, he notes, are where much of this biology originates, and the NIH only recently required that female mice be included, with sex as a biological variable written into most grant applications. He describes the field as emerging from "a long desert of absence of studies" into perimenopause. The two explanations are complementary rather than competing: a thin literature produces uncertain mechanism, and uncertain mechanism makes it hard to answer the practical question he then poses, which is whether ovarian sensitivity to FSH can be preserved or the transition prolonged.

Rather than argue the point abstractly, Haver quantifies it. A PubMed search for "pregnancy" returns "1.1 million articles"; the same search for "menopause" returns "97,000"; for "perimenopause" she found "like 6,400 and something" when she checked two weeks earlier. The ratios are the argument: the stage that occupies a third of a woman's life has a fraction of the literature of the reproductive years that precede it.

She ties the funding gap to outcomes. Later menopause is associated with better cardiometabolic health, and she frames the loss of estrogen as the thing that "accelerates our path to those diseases." That claim sets up the therapeutic question the episode will return to: if the transition is a hormonal withdrawal with downstream consequences, then the timing and mode of replacement become central rather than cosmetic.

"When you look at all NIH funding and what goes to menopause, it's 0.03%, less than half a percent", she says, against a stage she describes as "one third of a woman's life." The comparison is blunt, and it is the kind of figure that is easy to remember and hard to verify from inside a conversation; she does not cite the analysis behind it.

She also cites a McKinsey and Company report that pooled "680 studies" on chronic disease, including diabetes, hypertension and cardiovascular disease, and asked how many presented results separately by sex. Only "50% of the articles" did, she says, and among those that did, "30% of women had poorer outcomes" against "10% of men". Her conclusion is that the absence of sex-specific reporting is itself a clinical problem, and she adds a summary statistic of her own: women live longer than men, but "20 to 25% of that life is in poor health."

The policy discussion that follows is partly a list of recent vehicles. She mentions a bill signed into law carrying "a hundred million dollars" for women's health, which she says was divided quickly and gave menopause only a share, competing with endometriosis, uterine disease and PCOS. A second bill, which she associates with public advocacy by Halle Berry, would provide "$250 million" and, in her view more importantly, includes language for provider education. Her explanation for why education is the bottleneck is generational: she finished residency "the year the WHI came out", and after the Women's Health Initiative, menopause education "basically stopped", leaving a cohort of clinicians with little clinically significant training.

Huberman's contribution here is procedural rather than scientific. He describes the NIH as responsive to public demand, concedes that government moves slowly and that funding is finite, and then gives the plain version of lobbying: call your member of Congress and leave a message about a specific bill. He illustrates with the Brain Initiative, and he hedges the anecdote explicitly, saying "I'm probably going to get some details wrong." The exchange is a reminder that this stretch of the episode is advocacy as much as review, and that the numbers above are being deployed to make a case.

The best-documented consequences of the transition, she says, are psychiatric. Estrogen, progesterone and testosterone all act on neurotransmitter systems, and when their levels become chaotic, serotonin, norepinephrine and dopamine become unstable with them. She reports "at least a 40% increase" in mental health disorders across the transition and says SSRI use "doubles". The qualifier matters: the estimate is presented as a floor, not a point estimate.

From there she makes a stronger and more contestable claim. Women given hormone therapy during perimenopause, she says, have a lower incidence of new-onset depression, and she reports that some neuroscientists now argue that for women who develop depression in perimenopause, estrogen is the better intervention and will produce a better outcome than an SSRI. The attribution is to other researchers rather than to her own data, and no trial is named in this stretch, so the claim arrives as a reported shift in expert opinion rather than as settled evidence.

Huberman supplies the neurobiological context. He notes that estrogen and androgen receptors are distributed throughout the brain and nervous system, and that estrogen has direct relationships with serotonin, dopamine, epinephrine and acetylcholine; Haver adds GABA for progesterone. He draws on his own background in neural development, where hormones determine which neurons express which transmitters, and complains that neuroscience came late to treating hormones as central to brain health rather than as peripheral signals. The point is to correct a lay intuition that hormones act on the body while the brain merely issues commands.

The clinical picture she paints is broader than low mood. Anxiety rises. Executive function degrades, with what she describes as new-onset ADHD-type symptoms. "brain fog" shows up as lost words and an inability to perform calculations that were previously automatic, which matters most in jobs that depend on exactly those capacities. Her most arresting figure is that "One in five women will quit their jobs because of menopause symptoms."

She connects that attrition to timing. Perimenopause often arrives when children are grown and careers are positioned for leadership, so the loss is not only individual. Confidence collapses, sleep deteriorates, depression deepens, and the result is, in her words, "this horrible feedback cycle". Huberman calls the one-in-five figure "outrageous", and she notes its provenance: the number came "Out of the uk", and US analyses are "looking very similar." No study design, sample or definition is given, which is a limitation worth holding onto when the figure is repeated.

The gynecologic symptom she puts first is abnormal bleeding. Dysfunctional uterine bleeding covers heavy periods, cycles that are too frequent, too infrequent, or skipped entirely; "nothing's off the table." She estimates that "90% of us will have that as a symptom", and emphasizes severity rather than mere presence: some women lose enough blood, or have enough cramping, that the period becomes disabling.